2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
New biotech company focused on cell transplantation for Parkinson’s
Biotech company Ryne Bio has received a large research grant from CIRM to develop their late-stage preclinical cell transplantation procedure for Parkinson’s.
Sun Pharma shines on c-ABL
Sun Pharma have published data on their new drug vodobatinib which is a c-ABL inhibitor – c-ABL is over-active in the brains of people with Parkinson’s.
Biotech Inhibikase develops new drug for Parkinson’s
Researchers have published laboratory data demonstrating the neuroprotective effects of a new potential drug for Parkinson’s called IkT-148009.
Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Our 2022 research summary
2022 has seen Cure Parkinson’s emerge from the COVID pandemic with a bumper year of research activity; with clinical trial results being reported and exciting, innovative research projects being awarded funding. We are proud to share this end of year summary of some of these…